Drug updates and approvals: 2019 in review

被引：2

作者：

Crump, Lauren Hartsell ^{[1
]}

Benfield, Miranda ^{[2
]}

Ramey, Caleb ^{[3
]}

Arcara, Ashley ^{[3
]}

Yang, Sebin ^{[3
]}

Brown, Jenna ^{[3
]}

Mospan, Geoffrey ^{[3
]}

Mospan, Cortney ^{[3
]}

机构：

[1] Novara Hlth Presbyterian Med Ctr, Charlotte, NC 28204 USA

[2] Carolinas Med Ctr, Charlotte, NC 28203 USA

[3] Wingate Univ, Sch Pharm, Wingate, NC USA

来源：

NURSE PRACTITIONER | 2019年 / 44卷 / 12期

关键词：

corticosteroid; drug approvals; FDA; HIV; multiple sclerosis; narcolepsy; new drugs; obstructive sleep apnea; osteoporosis; postpartum depression; psoriasis; POSTMENOPAUSAL WOMEN; ROMOSOZUMAB; MANAGEMENT; DISEASE; TARGET; COPD;

D O I：

10.1097/01.NPR.0000605508.04187.b2

中图分类号：

R47 [护理学];

学科分类号：

1011 ;

摘要：

In 2019, the FDA approved several new drugs for use in primary care. This article highlights the following new drugs: risankizumab-rzaa (Skyrizi); halobetasol and tazarotene (Duobrii); dolutegravir and lamivudine (Dovato); romosozumab-aqqg (Evenity); brexanolone (Zulresso); solriamfetol (Sunosi); aclidinium and formoterol (Duaklir Pressair); and siponimod (Mayzent).

引用

页码：21 / 32

页数：12